← Mechanisms of action
FCGR3A
SINGLE PROTEINHomo sapiens
Preferred name: Low affinity immunoglobulin gamma Fc region receptor III-A ChEMBL ↗
Linked proteins
Drugs acting on this target (16)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| bgb-b3227 | Activator | experimental | mAb | FCGR3A activator |
| gtb-360 | Activator | experimental | mAb | FCGR3A activator |
| afm28 | Agonist | experimental | mAb | FCGR3A agonist |
| sar443579 | Agonist | experimental | mAb | FCGR3A agonist |
| sm3321 | Agonist | experimental | Small molecule | FCGR3A agonist |
| bemarituzumab | Binding agent | experimental | mAb | Low affinity immunoglobulin gamma Fc region receptor III-A binding agent |
| ft538 | Binding agent | experimental | Recombinant protein | FCGR3A binding agent |
| catumaxomab (Removab) | Cross-linking agent | experimental | mAb | FCGR3A cross-linking agent |
| imgatuzumab | Cross-linking agent | experimental | mAb | FCGR3A cross-linking agent |
| afm13 | Immunity, passive | experimental | mAb | FCGR3A immunity, passive |
| donor-derived cd123-cd16 bispecific antibody-modified nk cells | Immunity, passive | experimental | Cell therapy | FCGR3A immunity, passive |
| afm24 | Inhibitor | experimental | mAb | FCGR3A inhibitor |
| ANSUVIMAB (Ebanga) | Inhibitor | approved | mAb | FCGR3A inhibitor |
| gma161 | Inhibitor | experimental | mAb | FCGR3A inhibitor |
| gtb-3550 | Inhibitor | experimental | mAb | FCGR3A inhibitor |
| ro7297089 | Inhibitor | experimental | mAb | FCGR3A inhibitor |